Aging Liver and Hepatitis

Clinics in Geriatric Medicine

Volumn 23, Issue 4, 2007, Pages 889-903

  Junaidi, Omer ^a   Di Bisceglie, Adrian M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ADEFOVIR; ALPHA INTERFERON; AMANTADINE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ATORVASTATIN; AZATHIOPRINE; ENTECAVIR; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; ISONIAZID; LAMIVUDINE; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PEGINTERFERON; PEGINTERFERON ALPHA; PIOGLITAZONE; PLACEBO; RIBAVIRIN; ROSIGLITAZONE; STEROID; TROGLITAZONE; UNCLASSIFIED DRUG;

AUTOIMMUNE HEPATITIS; CHRONIC LIVER DISEASE; DRUG FATALITY; DRUG OVERDOSE; DRUG SUBSTITUTION; HEPATITIS; HEPATITIS A; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HYPERGAMMAGLOBULINEMIA; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; LIVER INJURY; LIVER REGENERATION; LIVER TOXICITY; MONOTHERAPY; MOON FACE; MORBIDITY; MORTALITY; NONHUMAN; PREVALENCE; REVIEW; RISK FACTOR; SIDE EFFECT; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT; VACCINATION;

AGED; AGING; HEPATITIS, AUTOIMMUNE; HEPATITIS, TOXIC; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER; RISK FACTORS;

EID: 34848890947     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2007.06.006     Document Type: Review

References (81)

1. Murphy S. Deaths: final data for 1998. National vital statistics reports vol. 48 (2000), National Center for Health Statistics, Hyattsville (MD)
2. Kim W.R., Brown Jr. R.S., Terrault N.A., et al. Burden of liver disease in the United States: summary of a workshop. Hepatology 36 1 (2002) 227-242
3. Wynne H.A., Cope L.H., Much E., et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 9 (1989) 297-301
4. Zoli M., Magalotti D., Bianchi G., et al. Total and functional hepatic blood flow decrease in parallel with ageing. Age Ageing 28 1 (1999) 29-33
5. Marchesisi G., Bua V., Brunori A., et al. Galactose elimination capacity and liver volume in aging man. Hepatology 8 5 (1988) 1079-1083
6. Popper H. Aging and the liver. In: Popper H., and Schaffner F. (Eds). Progress in liver diseases vol. 8 (1986), Grune & Stratton, New York 659-683
7. Schmucker D.L. Hepatocyte fine structure during maturation and senescence. J Electron Microsc Tech 14 2 (1990) 106-125
8. Tauchi H., and Sato T. Age changes in size and number of mitochondria of human hepatic cells. J Gerontol 23 4 (1968) 454-461
9. Williams D., and Woodhouse K. Age related changes in O-deethylase and aldrin epoxidase activity in mouse skin and liver microsomes. Age Aging 25 (1996) 377-380
10. Wynne H., Mutch E., James O.F., et al. The effect of age on mono-oxygenase enzyme kinetics in rat liver microsomes. Age Aging 16 (1987) 153-158
11. Le Couteur D.G., and McLean A.J. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 34 (1998) 359-373
12. Le Couteur D.G., Cogger V.C., Markus A.M., et al. Pseudocapillarization and associated energy limitation in the aged rat liver. Hepatology 33 (2001) 537-543
13. Sanz N., Diez-Fernandez C., Alvarez A.M., et al. Age related changes on parameters of experimentally-induced liver injury and regeneration. Toxicol Appl Pharmacol 154 (1999) 40-49
14. Schmucker D.L. Aging and the liver: an update. J Gerontol A Biol Sci Med Sci 53 (1998) B315-B320
15. Tsukamoto I., Nakata R., and Kojo S. Effect of aging on rat liver regeneration after partial hepatectomy. Biochem Mol Biol Int 30 (1993) 773-778
16. Liu Y., Guyton K.Z., Gorospe M., et al. Age-related decline in mitogen-activated protein kinase activity in epidermal growth factor-stimulated rat hepatocytes. J Biol Chem 271 (1996) 3604-3607
17. Wynne H.A., Yelland C., Cope L.H., et al. The association of age and frailty with the pharmacokinetics and pharmacodynamics of metoclopramide. Age Aging 22 (1993) 354-359
18. Wynne H.A., Cope L.H., Herd B., et al. The association of age and frailty with paracetamol conjugation in man. Age Aging 19 (1990) 419-424
19. Forbes A., and Williams R. Changing epidemiology and clinical aspects of hepatitis A. Br Med Bull 46 (1990) 303-318
20. Forbes A., and Williams R. Increasing age-an important adverse prognostic factor in hepatitis A virus infection. J R Coll Physicians Lond 22 (1988) 237-239
21. Brown G.R., and Persley K. Hepatitis A epidemic in the elderly. South Med J 95 (2002) 826-833
22. Willner I.R., Howard S.C., Williams E.Q., et al. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med 128 (1998) 111-114
23. Chien N.T., Dundoo G., Horani M.H., et al. Seroprevalence of viral hepatitis in an older nursing home population. J Am Geriatr Soc 47 (1999) 1110-1113
24. CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 48 No. RR-12 (1999) 1-37
25. Kondo Y., Tsukada K., Takeuchi T., et al. High carrier rate after hepatitis B virus infection in the elderly. Hepatology 18 (1993) 768
26. Sugauchi F., Mizokami M., Orito E., et al. Hepatitis B virus infection among residents of a nursing home for the elderly: seroepidemiological study and molecular evolutionary analysis. J Med Virol 62 (2000) 456-462
27. Liaw Y.F., Leung N., Guan R., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol 18 (2003) 239-245
28. Franchis R., Hadengue A., Lau G.K., et al. EASL Jury. EASL International Consensus Conference on Hepatitis B. J Hepatol 39 (2003) S3-S25
29. Lok A.S., and McMahon B.J. Chronic hepatitis B. Update of recommendations. Hepatology 39 (2004) 857-861
30. Li Y.H., He Y.F., Jiang W.Q., et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 106 6 (2006) 1320-1325
31. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: immunization of infants, children, and adolescents. Morbidity and Mortality Weekly Report 54 No. RR-16 (2005) 1-33
32. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 (1999) 556-562
33. WHO. Hepatitis C: global prevalence. Wkly Epidemiol Rec 72 (1997) 341-344
34. Alter M.J. Epidemiology of hepatitis C. Hepatology 26 Suppl 1 (1997) 62S-65S
35. Brind A.M., Watson J.P., James O.F.W., et al. Hepatitis C virus infection in the elderly. QJM 89 (1996) 291-296
36. Monica F., Lirussi F., Nassuato G., et al. Hepatitis C virus infection and related chronic liver disease in a resident elderly population: The Silea study. J Viral Hepat 5 (1998) 345-351
37. Strader D.B., Wright T., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C. American Association for the Study of Liver Diseases. Hepatology 39 (2004) 1147-1171
38. Gordon S.C., Elloway R.S., Long J.C., et al. The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology 18 (1993) 1338-1343
39. Yano M., Yatsuhashi H., Inokuchi K., et al. Epidemiology and long term prognosis off hepatitis C virus infection in Japan. Gut 34 Suppl 1 (1993) S13-S16
40. Poynard T., Bedossa P., and Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349 (1997) 825-832
41. Roudot-Thoraval F., Bastie A., Pawlotsky J.M., et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 26 (1997) 485-490
42. Floreani A., Bertin T., Soffiati G., et al. Anti-hepatitis C virus in the elderly: a seroepidemiological study in a home for the aged. Gerontology 38 (1992) 214-216
43. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon a-2b plus ribavirin compared with interferon a-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358 (2001) 958-965
44. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon a-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
45. Strader D.B. Understudied populations with hepatitis C. Hepatology 36 Suppl 1 (2002) S226-S236
46. Horiike N., Masumoto T., Nakanishi K., et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 10 (1995) 246-249
47. Marcus E.L., and Tur-Kaspa R. Viral hepatitis in older adults. J Am Geriatr Soc 45 (1997) 755-763
48. Bacosi M., Russo F., D'innocenzo S., et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatol Res 22 (2002) 231-239
49. Alessi N., Freni M.A., Spadaro A., et al. Efficacy of interferon treatment (IFN) in elderly patients with chronic hepatitis C. Infez Med 11 (2003) 208-212
50. Imai Y., Kasahara A., Tanaka H., et al. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. J Gastroenterol 39 (2004) 1069-1077
51. Shiratori Y., Ito Y., Yokosuka O., et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 142 (2005) 105-114
52. Thabut D., Le Calvez S., Thibault V., et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?. Am J Gastroenterol 101 6 (2006) 1260-1267
53. Nudo C.G., Wong P., Hilzenrat N., et al. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol 20 9 (2006) 589-592
54. Arias E. United States life tables, 2002. Natl Vital Stat Rep 53 (2004) 1-38
55. Waldenstrom J.L. Blutproteine und Nahrungseiweisse. [German]. Dtsch Gesellsch Verd Stoffw 15 (1950) 113-119
56. Kunkel H.G., Ahrens E.H.J., and Eisenmenger W.J. Extreme hypergammaglobulinemia in young women with liver disease of unknown etiology. J Clin Invest 30 (1951) 654
57. Mackay I.R., Taft L.I., and Cowling D.C. Lupoid hepatitis. Lancet 2 (1956) 1323-1326
58. McFarlane I.G. The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis. Gut 42 (1998) 599-602
59. Toda G., Zeniya M., Watanabe F., et al. Present status of autoimmune hepatitis in Japan, correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis. J Hepatol 26 (1997) 1207-1212
60. Schramm C., Kanzler S., Meyer zum Buschenfelde K.H., et al. Autoimmune hepatitis in the elderly. Am J Gastroenterol 96 (2001) 1587-1591
61. Parker D.R., and Kingham J.G. Type 1 autoimmune hepatitis is primarily a disease of later life. QJM 90 (1997) 289-296
62. Strassburg C.P., and Manns M.P. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis 22 (2002) 339-352
63. Donaldson P.T., Doherty D.G., Hayllar K.M., et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 13 (1991) 701-706
64. Yarze J.C., Meyer zum Buschenfelde K.-H., and Lohse A.W. Autoimmune hepatitis. N Engl J Med 334 (1996) 923-924
65. Lebovics E., Schaffner F., Klion F.M., et al. Autoimmune chronic active hepatitis in postmenopausal women. Dig Dis Sci 30 (1985) 824-828
66. Selby C.D., and Toghill P.J. Chronic active hepatitis in the elderly. Age Ageing 15 (1986) 350-356
67. Newton J.L., Burt A.D., Park J.B., et al. Autoimmune hepatitis in older patients. Age Ageing 26 (1997) 441-444
68. Al-Chalabi T., Boccato S., Portmann B.C., et al. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 45 (2006) 575-583
69. Galan M.V., Potts J.A., Siverman A.L., et al. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol 39 (2005) 64-67
70. Maddrey W.C. Clinicopathologic patterns of drug-induced liver disease. In: Kaplowitz N., and DeLeve L.D. (Eds). Drug-induced liver disease (2002), Marcel Dekker, New York 227-242
71. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 33 (2001) 308-310
72. Larson A.M., Polson J., Fontana R.J., et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 42 (2005) 1364-1372
73. Maddrey W.C. Isoniazid-induced liver disease. Semin Liver Dis 1 (1981) 77-84
74. Kopanoff D.E., Snider Jr. D.E., and Caras G.J. Isoniazid related hepatitis. Am Rev Respir Dis 117 (1978) 991-1001
75. Fountain F.F., Tolley E., Chrisman C.R., et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7 year evaluation from a public health tuberculosis clinic. Chest 128 (2005) 116-123
76. Tolman K.G. The liver and lovastatin. Am J Cardiol 89 (2002) 1374-1380
77. Hey-Hadavi J.H., Kuntze E., Luo D., et al. Tolerability of atorvastatin in a population aged > or =65 years: a retrospective pooled analysis of results from fifty randomized clinical trials. Am J Geriatr Pharmacother 4 2 (2006) 112-122
78. Chalasani N., Aljadhey H., Kesterson J., et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 126 (2004) 1287-1292
79. Khorashadi S., Hasson N.K., and Cheung R.C. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol 4 7 (2006) 902-907
80. Graham D.J., Drinkard C.R., and Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol 98 (2003) 175-179
81. Nagasaka S., Abe T., Kawakami A., et al. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success. Diabet Med 19 (2002) 344-348